Multiple studies found that patients harboring a functional somatic mutation in the BAP1 gene that binds to the BRCA1 and acts as a tumor suppressor gene did not respond well to everolimus and sunitinib treatments as compared to patients with wild-type BAP1 (80, 81). Here, BAP1 is linked to neoplasm.